Cargando…
Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives
The expression of estrogen receptors (ERs) in breast cancer (BC) represents a strong prognostic and predictive biomarker and directs therapeutic decisions in early and advanced stages. ER-low-positive BC, defined by the immunohistochemical (IHC) expression of ERs from 1% to 9%, constitutes a distinc...
Autores principales: | Malainou, Christina Panagiotis, Stachika, Nikolina, Damianou, Aikaterini Konstantina, Anastopoulos, Aristotelis, Ploumaki, Ioanna, Triantafyllou, Efthymios, Drougkas, Konstantinos, Gomatou, Georgia, Kotteas, Elias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670665/ https://www.ncbi.nlm.nih.gov/pubmed/37999126 http://dx.doi.org/10.3390/curroncol30110706 |
Ejemplares similares
-
Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
por: Drougkas, Konstantinos, et al.
Publicado: (2022) -
Bcl-2 pathway inhibition in solid tumors: a review of clinical trials
por: Ploumaki, Ioanna, et al.
Publicado: (2023) -
An overview of the role of telomeres and telomerase in pre‑neoplastic lesions (Review)
por: Karaviti, Eleftheria, et al.
Publicado: (2023) -
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
por: Gomatou, Georgia, et al.
Publicado: (2023) -
Tumor Dormancy: Implications for Invasion and Metastasis
por: Gomatou, Georgia, et al.
Publicado: (2021)